Multidisciplinary Treatment of Patients With Noonan Syndrome: A Consensus Statement
Methodological detailsmodified Delphi process, multidisciplinary steering committee, 25-member expert panel
- Modified Delphi process
- Multidisciplinary steering committee
- 25-member expert panel
Recommendations
As issued by the authors
- 100% agreement
Molecular characterization is important for diagnosis, prognosis and treatment decisions
- 100% agreement
A multidisciplinary approach to noonan syndrome (NS) treatment is necessary
- 100% agreement
Transition from pediatric to adult care needs improvement
- 100% agreement
Patients with hypertrophic cardiomyopathy (HCM) are at increased risk
- 100% agreement
Adherence to recombinant human growth hormone (rhGH) therapy should be monitored
- 100% agreement
Partial GH insensitivity should not exclude rhGH therapy
- 100% agreement
Safety concerns regarding rhGH therapy, particularly related to HCM and the risk of malignant neoplasms
Original publication
Multidisciplinary Treatment of Patients With Noonan Syndrome: A Consensus Statement. JAMA Netw Open. Published 1 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →